Using a Machine Learning Approach to Identify Key Biomarkers for Renal Clear Cell Carcinoma

References

• Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.029
   PubMed Web of Science ®Google Scholar
• Zhan C, Wang Z, Xu C, et al. Development and validation of a prognostic gene signature in clear cell renal cell carcinoma. Front Mol Biosci. 2021;8(45). doi:10.3389/fmolb.2021.609865
   Web of Science ®Google Scholar
• Li Y, Gong Y, Ning X, et al. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis. J Exp Clin Cancer Res. 2018;37(1):276. doi:10.1186/s13046-018-0924-y
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865–875. doi:10.1056/NEJM199609193351207
   PubMed Web of Science ®Google Scholar
• Liu H, Yang Y. Identification of mast cell-based molecular subtypes and a predictive signature in clear cell renal cell carcinoma. Front Mol Biosci. 2021;8(927). doi:10.3389/fmolb.2021.719982
   Web of Science ®Google Scholar
• Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25(11):1316–1322. doi:10.1200/jco.2006.06.1218
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611–1623. doi:10.1016/S0022-5347(05)65640-6
   PubMed Web of Science ®Google Scholar
• Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res. 2007;13(2 Pt 2):697s–702s. doi:10.1158/1078-0432.Ccr-06-2109
   PubMed Web of Science ®Google Scholar
• Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol. 2013;63(6):1101–1106. doi:10.1016/j.eururo.2013.02.022
   PubMed Web of Science ®Google Scholar
• Li F, Yang M, Li Y, et al. An improved clear cell renal cell carcinoma stage prediction model based on gene sets. BMC Bioinform. 2020;21(1):232. doi:10.1186/s12859-020-03543-0
   PubMed Web of Science ®Google Scholar
• Cai W, Li H, Zhang Y, Han G. Identification of key biomarkers and immune infiltration in the synovial tissue of osteoarthritis by bioinformatics analysis. PeerJ. 2020;8:e8390. doi:10.7717/peerj.8390
   PubMed Web of Science ®Google Scholar
• Huang Y, Zheng S, Wang R, Tang C, Zhu J, Li J. CCL5 and related genes might be the potential diagnostic biomarkers for the therapeutic strategies of rheumatoid arthritis. Clin Rheumatol. 2019;38(9):2629–2635. doi:10.1007/s10067-019-04533-1
   PubMed Web of Science ®Google Scholar
• Chen Y, Liao R, Yao Y, Wang Q, Fu L. Machine learning to identify immune-related biomarkers of rheumatoid arthritis based on WGCNA network. Clin Rheumatol. 2021. doi:10.1007/s10067-021-05960-9
   Web of Science ®Google Scholar
• Tibshirani R. Regression shrinkage and selection via the lasso. J Royal Stat Soc Series B. 1996;58(1):267–288.
   Google Scholar
• Suzuki T, Kano S, Suzuki M, et al. Enhanced angiogenesis in salivary duct carcinoma ex-pleomorphic adenoma. Front Oncol. 2020;10:603717. doi:10.3389/fonc.2020.603717
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gómez L, Vohryzek J, Chiêm B, et al. Stable biomarker identification for predicting schizophrenia in the human connectome. Neuroimage Clin. 2020;27:102316. doi:10.1016/j.nicl.2020.102316
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41(D1):D991–5. doi:10.1093/nar/gks1193
   PubMed Web of Science ®Google Scholar
• Gumz ML, Zou H, Kreinest PA, et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 2007;13(16):4740–4749. doi:10.1158/1078-0432.Ccr-07-0143
   PubMed Web of Science ®Google Scholar
• Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer. 2003;3:31. doi:10.1186/1471-2407-3-31
   PubMed Web of Science ®Google Scholar
• von Roemeling CA, Radisky DC, Marlow LA, et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res. 2014;74(17):4796–4810. doi:10.1158/0008-5472.Can-14-0210
   PubMed Web of Science ®Google Scholar
• Wozniak MB, Le Calvez-kelm F, Abedi-Ardekani B, et al. Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States. PLoS One. 2013;8(3):e57886. doi:10.1371/journal.pone.0057886
   PubMed Web of Science ®Google Scholar
• Zhu YX, Huang JQ, Ming YY, Zhuang Z, Xia H. Screening of key biomarkers of tendinopathy based on bioinformatics and machine learning algorithms. PLoS One. 2021;16(10):e0259475. doi:10.1371/journal.pone.0259475
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Antonacci Y, Toppi J, Mattia D, Pietrabissa A, Astolfi L. Single-trial connectivity estimation through the least absolute shrinkage and selection operator. Annu Int Conf IEEE Eng Med Biol Soc. 2019;2019:6422–6425. doi:10.1109/embc.2019.8857909
   PubMedGoogle Scholar
• Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 2011;12:77. doi:10.1186/1471-2105-12-77
   PubMed Web of Science ®Google Scholar
• Sanz H, Valim C, Vegas E, Oller JM, Reverter F. SVM-RFE: selection and visualization of the most relevant features through non-linear kernels. BMC Bioinform. 2018;19(1). doi:10.1186/s12859-018-2451-4
   PubMed Web of Science ®Google Scholar
• Deng YJ, Ren E, Yuan WH, Zhang GZ, Xie QQ, Xie -Q-Q. GRB10 and E2F3 as diagnostic markers of osteoarthritis and their correlation with immune infiltration. Diagnostics. 2020;10(3):171. doi:10.3390/diagnostics10030171
   Web of Science ®Google Scholar
• Cao Y, Tang W, Tang W. Immune cell infiltration characteristics and related core genes in lupus nephritis: results from bioinformatic analysis. BMC Immunol. 2019;20. doi:10.1186/s12865-019-0316-x
   Web of Science ®Google Scholar
• Garza Z, Lenz M, Liebmann J, et al. Characterization of disease-specific cellular abundance profiles of chronic inflammatory skin conditions from deconvolution of biopsy samples. BMC Med Genomics. 2019;12:1–4.
   PubMed Web of Science ®Google Scholar
• Yang L, Shou YH, Yang YS, Xu JH. Elucidating the immune infiltration in acne and its comparison with rosacea by integrated bioinformatics analysis. PLoS One. 2021;16(3):e0248650. doi:10.1371/journal.pone.0248650
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830.e14. doi:10.1016/j.immuni.2018.03.023
   PubMed Web of Science ®Google Scholar
• Beck AH, Espinosa I, Edris B, et al. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res. 2009;15(3):778–787. doi:10.1158/1078-0432.Ccr-08-1283
   PubMed Web of Science ®Google Scholar
• Calabrò A, Beissbarth T, Kuner R, et al. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat. 2009;116(1):69–77. doi:10.1007/s10549-008-0105-3
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, Gomez S, Arenas A, et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer. 2010;10:604. doi:10.1186/1471-2407-10-604
   PubMed Web of Science ®Google Scholar
• Wolf DM, Lenburg ME, Yau C, Boudreau A, van ‘t Veer LJ. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One. 2014;9(2):e88309. doi:10.1371/journal.pone.0088309
   PubMed Web of Science ®Google Scholar
• Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004;2(2):E7. doi:10.1371/journal.pbio.0020007
   PubMed Web of Science ®Google Scholar
• Castiblanco-Valencia MM, Fraga TR, Pagotto AH, et al. Plasmin cleaves fibrinogen and the human complement proteins C3b and C5 in the presence of Leptospira interrogans proteins: a new role of LigA and LigB in invasion and complement immune evasion. Immunobiology. 2016;221(5):679–689. doi:10.1016/j.imbio.2016.01.001
   PubMed Web of Science ®Google Scholar
• Guglietta S, Rescigno M. Hypercoagulation and complement: connected players in tumor development and metastases. Semin Immunol. 2016;28(6):578–586. doi:10.1016/j.smim.2016.10.011
   PubMed Web of Science ®Google Scholar
• Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R, Kesharwani P. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discov Today. 2020;25(1):223–229. doi:10.1016/j.drudis.2019.11.003
   PubMed Web of Science ®Google Scholar
• Li J, Wang G, Zhang W, et al.Graphene film-functionalized germanium as a chemically stable, electrically conductive, and biologically active substrate. J Mater Chem B Mater Biol Med. 2015;3:1544–1555.
   PubMed Web of Science ®Google Scholar
• Young-Jun P, Da-sol K, Yeonseok C. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med. 2018;50(8):109.
   PubMedGoogle Scholar
• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. J Urol. 2012;188(6):2148–2149. doi:10.1016/j.juro.2012.08.169
   PubMed Web of Science ®Google Scholar
• La Paglia L, Listì A, Caruso S, et al. Potential role of ANGPTL4 in the cross talk between metabolism and cancer through PPAR signaling pathway. PPAR Res. 2017;2017:8187235. doi:10.1155/2017/8187235
   PubMed Web of Science ®Google Scholar
• Oike Y, Yasunaga K, Ito Y, et al. Angiopoietin-related growth factor (AGF) promotes epidermal proliferation, remodeling, and regeneration. Proc Natl Acad Sci. 2003;100(16):9494–9499. doi:10.1073/pnas.1531901100
   PubMed Web of Science ®Google Scholar
• Oike Y, Ito Y, Maekawa H. Angiopoietin-related growth factor (AGF) promotes angiogenesis. Blood. 2004;103(10):3760–3765. doi:10.1182/blood-2003-04-1272
   PubMed Web of Science ®Google Scholar
• Wang Y, Lam KS, Lam JB, et al.Overexpression of angiopoietin-like protein 4 alters mitochondria activities and modulates methionine metabolic cycle in the liver tissues of db/db diabetic mice. Chin Biol Abstract. 2007;21(11):1.
   Google Scholar
• Oike Y, Akao M, Yasunaga K, et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med. 2005;11(43):400–408. doi:10.1038/nm1214
   PubMed Web of Science ®Google Scholar
• Ge H, Cha J-Y, Gopal H, et al. Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res. 2005;46(7):1484–1490. doi:10.1194/jlr.M500005-JLR200
   PubMed Web of Science ®Google Scholar
• Xu A, Lam MC, Chan KW, et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci. 2005;102(17):6086–6091. doi:10.1073/pnas.0408452102
   PubMed Web of Science ®Google Scholar
• Li H, Ge C, Zhao F, et al.Hypoxia‐inducible factor 1 alpha–activated angiopoietin‐like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule‐1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology. 2011;54(3):910–919.
   PubMed Web of Science ®Google Scholar
• Kim SH, Park YY, Kim SW, Lee JS, Wang D, Dubois RN. ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res. 2011;71(22):7010. doi:10.1158/0008-5472.CAN-11-1262
   PubMed Web of Science ®Google Scholar
• Zhang H, Wong C, Wei H, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene. 2012;31(14):1757–1770. doi:10.1038/onc.2011.365
   PubMed Web of Science ®Google Scholar
• Jan SL, Amy C, Cazes A, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol. 2003;162(5):1521–1528. doi:10.1016/S0002-9440(10)64285-X
   PubMed Web of Science ®Google Scholar
• Verine J, Lehmann-Che J, Soliman H, et al. Determination of Angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS One. 2010;5:e10421. doi:10.1371/journal.pone.0010421
   PubMed Web of Science ®Google Scholar
• Galaup A, Cazes A, Le jan S, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA. 2006;103(49):18721–18726. doi:10.1073/pnas.0609025103
   PubMed Web of Science ®Google Scholar
• Cazes A, Galaup A, Chomel C. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ Res. 2006;99(11):1207–1215. doi:10.1161/01.RES.0000250758.63358.91
   PubMed Web of Science ®Google Scholar
• Dong D, Jia L, Zhou Y, Ren L, Li J, Zhang J. Serum level of ANGPTL4 as a potential biomarker in renal cell carcinoma. Urol Oncol. 2017;35(5):279–285. doi:10.1016/j.urolonc.2016.12.017
   PubMed Web of Science ®Google Scholar
• Sarver AE, Sarver AL, Thayanithy V, Subramanian S. Identification, by systematic RNA sequencing, of novel candidate biomarkers and therapeutic targets in human soft tissue tumors. Lab Invest. 2015;95(9):1077–1088. doi:10.1038/labinvest.2015.80
   PubMed Web of Science ®Google Scholar
• Sato M, Mamada H, Anzai N, Shirasaka Y, Nakanishi T, Tamai I. Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human. Biol Pharm Bull. 2010;33(3):498–503. doi:10.1248/bpb.33.498
   PubMed Web of Science ®Google Scholar
• Srimaroeng C, Perry JL, Pritchard JB. Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica. 2008;38(7–8):889–935. doi:10.1080/00498250801927435
   PubMed Web of Science ®Google Scholar
• Kang W, Zhang M, Wang Q, et al. The SLC family are candidate diagnostic and prognostic biomarkers in clear cell renal cell carcinoma. Biomed Res Int. 2020;2020:1932948. doi:10.1155/2020/1932948
   PubMed Web of Science ®Google Scholar